Akebia Therapeutics
AKBA
165 hedge funds and large institutions have $190M invested in Akebia Therapeutics in 2025 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 63 increasing their positions, 48 reducing their positions, and 33 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 48
26% more call options, than puts
Call options by funds: $976K | Put options by funds: $773K
2.1% less ownership
Funds ownership: 46.64% → 44.54% (-2.1%)
7% less funds holding
Funds holding: 177 → 165 (-12)
30% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 33
44% less capital invested
Capital invested by funds: $338M → $190M (-$147M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$6.15M |
| 2 |
State Street
Boston,
Massachusetts
|
+$3.86M |
| 3 |
HF
HRT Financial
New York
|
+$3.34M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.1M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$1.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$7.89M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
-$6.69M |
| 3 |
Morgan Stanley
New York
|
-$6.46M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.81M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$5.23M |
AKBA Hedge Fund Activity: Q4 2025 in Review
165 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q4 2025, worth a combined $190M — down 44% from $338M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of AKBA and 23 opened new positions — a net loss of 10 holders — while 48 trimmed existing stakes and 63 added.
The largest buyer was Goldman Sachs, adding an estimated $6.15M. The largest seller was MPM BioImpact, exiting entirely with an estimated $7.89M sold.
- 165 institutional investors held Akebia Therapeutics (AKBA) as of Q4 2025, down from 177 in Q3 2025.
- Funds reported $190M of Akebia Therapeutics stock for Q4 2025, down 44% quarter-over-quarter.
- 23 funds opened new Akebia Therapeutics positions in Q4 2025 and 33 closed out, a net change of -10 holders.
- The largest Akebia Therapeutics buyer in Q4 2025 was Goldman Sachs, an estimated $6.15M added.
- The largest Akebia Therapeutics seller in Q4 2025 was MPM BioImpact, an estimated $7.89M sold.
Based on aggregated 13F filings for Q4 2025.